Cytokine-induced changes in mood and behaviour: Implications for 'depression due to a general medical condition', immunotherapy and antidepressive treatment

International Journal of Neuropsychopharmacology

Volumn 5, Issue 4, 2002, Pages 389-399

  Pollak, Yehuda ^a   Yirmiya, Raz ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Antidepressants; Cytokines; Illness associated depression; Immunotherapy

Indexed keywords

ANTIDEPRESSANT AGENT; BRAIN MONOAMINE; CYTOKINE; ROLIPRAM; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ANTIINFLAMMATORY ACTIVITY; BEHAVIOR DISORDER; CANCER THERAPY; COMORBIDITY; CYTOKINE RELEASE; DEPRESSION; DISEASE SEVERITY; DYSTHYMIA; HEPATITIS; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOTHERAPY; INFLAMMATION; MELANCHOLIA; MENTAL DISEASE; MENTAL STRESS; MONOAMINERGIC SYSTEM; MOOD DISORDER; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; REVIEW;

AFFECT; ANIMALS; ANTIDEPRESSIVE AGENTS; BEHAVIOR; BEHAVIOR, ANIMAL; CYTOKINES; DEPRESSIVE DISORDER; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; IMMUNE SYSTEM; IMMUNOTHERAPY;

EID: 0036904039     PISSN: 14611457     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1461145702003152     Document Type: Review

References (121)

1. Anisman H, Ravindran AV, Griffith J, Merali Z (1999). Interleukin-1β production in dysthymia before and after pharmacotherapy. Biological Psychiatry 46, 1649-1655.
2. APA (1994). Diagnostic and Statistical Manual of Mental Disorders (4th Edn). Washington, DC: American Psychiatric Association.
3. Benazzi F (2000). Late-life chronic depression: A 399-case study in private practice. International Journal of Geriatric Psychiatry 15, 1-6.
4. Besedovsky HO, Del Rey A (1996). Immune-neuro-endocrine interactions: Facts and hypotheses. Endocrine Reviews 17, 64-102.
5. Bianchi M, Panerai AE (1996). Antidepressant drugs and experimental inflammation. Pharmacological Research 33, 235-238.
6. Black SA, Markides KS (1999). Depressive symptoms and mortality in older Mexican Americans. Annals of Epidemiology 9, 45-52.
7. Bode L, Durrwald R, Rantam FA, Ferszt R, Ludwig H (1996). First isolation of infectious human Borna disease virus from patients with mood disorders. Molecular Psychiatry 1, 200-212.
8. Bonaccorso S, Marino V, Puzella A, Pasquini M, Biondi M, Artini M, Almerighi C, Verkerk R, Meltzer HY, Maes M (2002). Increased depressive ratings in patients with hepatitis C receiving interferon-a-based immunotherapy are related to interferon-a-induced changes in the serotonergic system. Journal of Clinical Psychopharmacology 22, 86-90.
9. Bonaccorso S, Puzella A, Marino V, Pasquini M, Biondi M, Artini M, Almerighi C, Levero M, Egyed B, Bosmans E, Meltzer HY, Maes M (2001). Immunotherapy with interferon-α in patients affected by chronic hepatitis C induces an intercorrelated stimulation of the cytokine network and an increase in depressive and anxiety symptoms. Psychiatry Research 15, 45-55.
10. Cappel R, Gregoire E, Thiry L, Sprecher S (1978). Antibody and cell-mediated immunity to herpes simplex virus in psychotic depression. Journal of Clinical Psychiatry 39, 266-268.
11. Capuron L, Lamarque D, Dantzer R, Goodall G (1999). Attentional and mnemonic deficits associated with infectious disease in humans. Psychological Medicine 29, 291-297.
12. Capuron L, Miller AH, Ravaud A, Neveu PJ, Maes M, Dantzer R (2001b). Brain, Behavior and Immunity 15, 139-140.
13. Capuron L, Ravaud A, Dantzer R (2000). Early depressive symptoms in cancer patients receiving interleukin2 and/or interferon α-2b therapy. Journal of Clinical Oncology 18, 2143-2151.
14. Capuron L, Ravaud A, Gualde N, Bosmans E, Dantzer R, Maes M, Neveu PJ (2001a). Association between immune activation and early depressive symptoms in cancer patients treated with interleukin-2-based therapy. Psychoneuroendocrinology 26, 797-808.
15. Castanon N, Bluthé RM, Dantzer R (2001). Chronic treatment with the atypical antidepressant tianeptine attenuates sickness behavior induced by peripheral but not central lipopolysaccharide and interleukin-1β in the rat. Psychopharmacology 154, 50-60.
16. Castanon N, Médina C, Mormède C, Dantzer R (In Press). Chronic treatment with the antidepressant tianeptine attenuates splenic and brain expression of pro-inflammatory cytokines. Brain, Behavior and Immunity.
17. Charney DS (1998). Monoamine dysfunction and the pathophysiology and treatment of depression. Journal of Clinical Psychiatry 59, S11-S14.
18. Cole MG, Bellvance F, Mansour A (1999). Prognosis of depression in elderly community and primary care populations: A systematic review and meta-analysis. American Journal of Psychiatry 156, 1182-1189.
19. Connor TJ, Leonard BE (1998). Depression, stress and immunological activation: The role of cytokines in depressive disorders. Life Science 62, 583-606.
20. Dantzer R (2001). Cytokine-induced sickness behavior: Where do we stand? Brain Behavior and Immunity 15, 7-24.
21. Dantzer R, Konsman JP, Bluthe RM, Kelley KW (2000). Neural and humoral pathways of communication from the immune system to the brain: Parallel or convergent? Autonomic Neuroscience 20, 60-65.
22. Dantzer R, Wollman EE, Vitkovic L, Yirmiya R (1999). Cytokines and depression: Fortuitous or causative associations? Molecular Psychiatry 4, 328-332.
23. Delgado PL (2000). Depression: The case for a monoamine deficiency. Journal of Clinical Psychiatry 61, S7-S11.
24. Dieperink E, Willenbring M, Ho SB (2000). Neuropsychiatric symptoms associated with hepatitis C and interferon a: A review. American Journal of Psychiatry 157, 867-876.
25. Dunn AJ, Swiergiel AH (2001). The reductions in sweetened milk intake induced by interleukin-1 and endotoxin are not prevented by chronic antidepressant treatment. Neuroimmunomodulation 9, 163-169.
26. Dunn AJ, Wang J, Ando T (1999). Effects of cytokines on cerebral neurotransmission. Comparison with the effects of stress. Advances in Experimental Medicine and Biology 461, 117-127.
27. Fassbender K, Schmidt R, Mossner R, Kischka U, Kuhnen J, Schwartz A, Hennerici M (1998). Mood disorders and dysfunction of the hypothalamic-pituitary-adrenal axis in multiple sclerosis: Association with cerebral inflammation. Archives of Neurology 55, 66-72.
28. Foley FW, Traugott U, LaRocca NG, Smith CR, Perlman KR, Caruso LS, Scheinberg LC (1992). A prospective study of depression and immune dysregulation in multiple sclerosis. Archives of Neurology 49, 238-244.
29. Gavard JA, Lustman PJ, Clouse RE (1993). Prevalence of depression in adults with diabetes. Diabetes Care 16, 1167-1178.
30. Gottfries CG (1997). Recognition and management of depression in the elderly. International Clinical Psychopharmacology 12, S31-S36.
31. Haack M, Hinze Selch D, Fenzel T, Kraus T, Kuhn M, Schuld A, Pollmächer T (1999). Plasma levels of cytokines and soluble cytokine receptors in psychiatric patients upon hospital admission: Effects of confounding factors and diagnosis. Journal of Psychiatric Research 33, 407-418.
32. Holsboer F (2000). The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology 23, 477-501.
33. Hosaka T, Aoki T, Watanabe T, Okuyama T, Kurosawa H (1999). Comorbidity of depression among physically ill patients and its effect of hospital stay. Psychiatry and Clinical Neuroscience 53, 491-495.
34. Hutchinson GA, Nehall JE, Simeon DT (1996). Psychiatric disorders in systemic lupus erythematosus. West Indian Medical Journal 45, 48-50.
35. Ignatowski TA, Noble BK, Wright JR, Gorfien JL, Heffner RR, Spengler RN (1997). Neuronal-associated tumor necrosis factor (TNF-α): Its role in noradrenergic functioning and modification of its expression following antidepressant drug administration. Journal of Neuroimmunology 79, 84-90.
36. Iwagaki H, Hizuta A, Uomoto M, Takeuchi Y, Saito S, Tanaka N (1997). Cancer cachexia and depressive states: A neuroendocrine-immunological disease? Acta Medica Okayama 51, 233-236.
37. Kendler KS, Karkowsky LM, Prescott CA (1999). Causal relationship between stressful life events and the onset of major depression. American Journal of Psychiatry 156, 837-841.
38. Konan KW, Taylor MW (1996). Importance of the two interferon-stimulated response element (ISRE) sequences in the regulation of the human indoleamine 2,3-dioxygenase gene. Journal of Biological Chemistry 271, 19140-19145.
39. Kubera M, Holan V, Mathison R, Maes M (2000b). The effect of repeated amitriptyline and desipramine administration on cytokine release in C57BL/6 mice. Psychoneuroendocrinology 25, 785-797.
40. Kubera M, Kenis G, Bosmans E, Jaworska-Feil L, Lason W, Scharpe S, Maes M (2000a). Suppressive effect of TRH and imipramine on human interferon-γ and interleukin-10 production in vitro. Polish Journal of Pharmacology 52, 481-486.
41. Kubera M, Kenis G, Bosmans E, Zieba A, Dudek D, Nowak G, Maes M (2000c). Plasma levels of interleukin-6, interleukin-10, and interleukin-1 receptor antagonist in depression: Comparison between the acute state and after remission. Polish Journal of Pharmacology 52, 237-241.
42. Kubera M, Lin AH, Kenis G, Bosmans E, Van-Bockstaele D, Maes M (2001a). Anti-inflammatory effects of antidepressants through suppression of the interferon-γ/interleukin-10 production ratio. Journal of Clinical Psychopharmacology 21, 199-206.
43. Kubera M, Maes M, Holan V, Basta Kaim A, Roman A, Shani J (2001b). Prolonged desipramine treatment increases the production of interleukin-10, an anti-inflammatory cytokine, in C57BL/6 mice subjected to the chronic mild stress model of depression. Journal of Affective Disorders 63, 171-178.
44. Kubera M, Symbirtsev A, Basta-Kaim A, Borycz J, Roman A, Papp M, Claesson M (1996). Effect of chronic treatment with imipramine on interleukin-1 and interleukin-2 production by splenocytes obtained from rats subjected to chronic mild stress model of depression. Polish Journal of Pharmacology 48, 503-506.
45. Lacosta S, Merali Z, Anisman H (2000). Central monoamine activity following acute and repeated systemic interleukin-2 administration. Neuroimmunomodulation 8, 83-90.
46. Landmann R, Schaub B, Link S, Wacker HR (1997). Unaltered monocyte function in patients with major depression before and after three months of antidepressive therapy. Biological Psychiatry 41, 675-681.
47. Larson SJ, Dunn AJ (2001). Behavioral effects of cytokines. Brain, Behavior and Immunity 15, 371-387.
48. Lauritzen L, Bendsen BB, Vilmar T, Bendsen EB, Lunde M, Bech P (1994). Post-stroke depression: Combined treatment with imipramine or desipramine and mianserin. Psychopharmacology 114, 119-122.
49. Lee Y, Choi K, Lee YK (2001). Association of comorbidity with depressive symptoms in community-dwelling older persons. Gerontology 47, 254-262.
50. Leonard B (2001). The immune system, depression and the action of antidepressants. Progress in Neuro-Psychopharmacology and Biological Psychiatry 25, 767-780.
51. Lestage J, Gaunt D, Pehourcq F, Dantzer R (In Press). Evidence for induction of IDO in the brain in response to peripheral immune stimuli. Brain, Behavior and Immunity.
52. Leu SJ, Shiah IS, Yatham LN, Cheu YM, Lam RW (2001). Immune-inflammatory markers in patients with seasonal affective disorder: Effects of light therapy. Journal of Affective Disorders 63, 27-34.
53. Linthorst AC, Reul JM (1998). Brain neurotransmission during peripheral inflammation. Annals of New York Academy of Sciences 840, 139-152.
54. Lycke E, Norrby R, Roos BE (1974). A serological study on mentally ill patients with particular reference to prevalence of herpes simplex virus infections. British Journal of Psychiatry 124, 273.
55. Maes M (1995). Evidence for an immune response in major depression: A review and hypothesis. Progress in Neuro-Psychopharmaclogy and Biological Psychiatry 19, 11-38.
56. Maes M (1999). Major depression and activation of the inflammatory response system. Advances in Experimental Medicine and Biology 461, 25-46.
57. Maes M, Bonaccorso S, Marino V, Puzella A, Pasquini M, Biondi M, Artini M, Almerighi C, Meltzer H (2001b). Treatment with interferon-α (IFN-α) of hepatitis C patients induces lower serum dipeptidyl peptidase IV activity, which is related to IFN-α-induced depressive and anxiety symptoms and immune activation. Molecular Psychiatry 6, 475-480.
58. Maes M, Bosmans E, Meltzer HY (1995). Immunoendocrine aspects of major depression. Relationships between plasma interleukin-6 and soluble interleukin-2 receptor, prolactin and cortisol. European Archives of Psychiatry and Clinical Neuroscience 245, 172-178.
59. Maes M, Capuron L, Ravaud A, Gualde N, Bosmans E, Egyed B, Dantzer R, Neveu PJ (2001a). Lowered serum dipeptidyl peptidase IV activity is associated with depressive symptoms and cytokine production in cancer patients receiving interleukin-2-based immunotherapy. Neuropsychopharmacology 24, 130-140.
60. Maes M, Meltzer HY, Scharpe S, Cooreman W, Uyttenbroeck W, Suy E, Vandervorst C, Calabrese J, Raus J, Cosyns P (1993). Psychomotor retardation, anorexia, weight loss, sleep disturbances, and loss of energy: Psychopathological correlates of hyperhaptoglobinemia during major depression. Psychiatry Research 47, 229-241.
61. Maes M, Ombelet W, Verkerk R, Bosmans E, Scharpe S (2001c). Effects of pregnancy and delivery on the availability of plasma tryptophan to the brain: Relationships to delivery-induced immune activation and early post-partum anxiety and depression. Psychological Medicine 31, 847-858.
62. Maes M, Song C, Lin A-h, Bonaccorso S, Kenis G, De Jongh R, Bosmans E, Scharpe S (1999). Negative immunoregulatory effects of antidepressants: Inhibition of interferon-γ and stimulation of interleukin-10 secretion. Neuropsychopharmacology 20, 370-379.
63. Maes M, Vandoolaeghe E, Van Hunsel F, Bril T, Demedts P, Wauters A, Neels H (1997). Immune disturbances in treatment-resistant depression: Modulation by antidepressive treatment. Human Psychopharmacology 12, 153-162.
64. Maier SF, Watkins LR (1998). Cytokines for psychologists: Implications of bi-directional immune-to-brain communication for understanding behavior, mood, and cognition. Psychological Review 105, 83-107.
65. Maj M (1996). Depressive syndromes and symptoms in subjects with human immunodeficiency virus (HIV) infection. British Journal of Psychiatry 168, 117-122.
66. Meyers CA (1999). Mood and cognitive disorders in cancer patients receiving cytokine therapy. Advances in Experimental Medicine and Biology 461, 75-81.
67. Mikova O, Yakimova R, Bosmans E, Kenis G, Maes M (2001). Increased serum tumor necrosis factor alpha concentrations in major depression and multiple sclerosis. European Neuropsychopharmacology 11, 203-208.
68. Mills TL (2001). Comorbid depressive symptomatology: Isolating the effects of chronic medical conditions on self-reported depressive symptoms among community-dwelling older adults. Social Science and Medicine 53, 569-578.
69. Mohr DC, Goodkin DE, Islar J, Hauser SL, Genain CP (2001). Treatment of depression is associated with suppression of nonspecific and antigen-specific T(H)1 responses in multiple sclerosis. Archives of Neurology 58, 1081-1086.
70. Morag M, Yirmiya R, Lerer B, Morag A (1998). Influence of socioeconomic status on behavioral, emotional, and cognitive effects of rubella vaccination: A prospective, double blind study. Psychoneuroendocrinology 23, 337-351.
71. Morikawa O, Sakai N, Obara H, Saito N (1998). Effects of interferon-α, interferon-γ and cAMP on the transcriptional regulation of the serotonin transporter. European Journal of Pharmacology 348, 317-324.
72. Mossner R, Daniel S, Schmitt A, Albert D, Lesch KP (2001). Modulation of serotonin transporter function by interleukin-4. Life Science 68, 873-880.
73. Mossner R, Heils A, Stober G, Okaldnova O, Daniel S, Lesch KP (1998). Enhancement of serotonin transporter function by tumor necrosis a but not by interleukin-6. Neurochemistry International 33, 251-254.
74. 2. Prostaglandins 4, 25-132.
75. Musselman DL, Lawson DH, Gumnick JF, Manatunga AK, Penna S, Goodkin RS, Greiner K, Nemeroff CB, Miller AH (2001). Paroxetine for the prevention of depression induced by high dose interferon alpha. New England Journal of Medicine 344, 961-969.
76. Natelson BH, Denny T, Zhou XD, LaManca JJ, Ottenweller LE, Tiersky L. DeLuca J, Gause WC (1999). Is depression associated with immune activation? Journal of Affective Disorders 53, 179-184.
77. Nickola TJ, Ignatowski TA, Reynolds JL, Spengler RN (2001). Antidepressant drug-induced alterations in neuron-localized tumor necrosis factor-a mRNA and a(2)-adrenergic receptor sensitivity. Journal of Pharmacology and Experimental Therapeutics 297, 680-687.
78. Patten SB (2001). Long-term medical conditions and major depression in a Canadian population study at waves 1 and 2. Journal of Affective Disorders 63, 35-41.
79. Peter D, White MD (1999). Do viruses cause depressive illness? General Hospital Psychiatry 21, 18-20.
80. Pincus T, Griffith J, Pearce S, Isenberg D (1996). Prevalence of self-reported depression in patients with rheumatoid arthritis. British Journal of Rheumatology 35, 879-883.
81. Plotsky PM, Owens MJ, Nemeroff CB (1998). Psychoneuroendocrinology of depression. Hypothalamicpituitary-adrenal axis. Psychiatric Clinics of North America 21, 293-307.
82. Rabkin JG, Wagner G, Rabkin R (1994). Effects of sertraline on mood and immune status in patients with major depression and HIV illness: An open trial. Journal of Clinical Psychiatry 55, 433-439.
83. Raison CL, Miller AH (2001). The neuroimmunology of stress and depression. Seminars in Clinical Neuropsychiatry 6, 277-294.
84. Ramamoorthy S, Ramamoorthy JD, Prasad PD, Bhat GK, Mahesh VB, Leibach FH, Ganapathy V (1995). Regulation of the human serotonin transporter by interleukin-1β. Biochemical and Biophysical Research Communications 216, 560-567.
85. Reichenberg A, Schuld A, Kraus T, Haack M, Pollmächer T, Yirmiya R (In Press). Endotoxin-induced anorexia in healthy human volunteers is mediated by cytokine secretion. Psychoneuroendocrinology.
86. Reichenberg A, Yirmiya R, Schuld A, Kraus T, Haack M, Pollmächer T (2001). Endotoxin-induced emotional and cognitive disturbances in healthy volunteers are associated with increased plasma levels of cytokines and cortisol. Archives of General Psychiatry 58, 445-452.
87. Robinson RG (1997). Neuropsychiatric consequences of stroke. Annual Review of Medicine 48, 217-229.
88. Rodin G, Voshart K (1986). Depression in the medically ill: An overview. American Journal of Psychiatry 143, 696-705.
89. Rothermundt M, Arolt V, Fenker J, Gutbrodt H, Peters M, Kersting A, Kirchner H (2001b). Inflammatory markers in major depression and melancholia. Journal of Affective Disorders 63, 93-102.
90. Rothermundt M, Arolt V, Fenker J, Gutbrodt H, Peters M, Kirchner H (2001a). Different immune patterns in melancholic and non-melancholic major depression. European Archives of Psychiatry and Clinical Neuroscience 251, 90-97.
91. Schiffer RB, Babigian HM (1984). Behavioral disorders in multiple sclerosis, temporal lobe epilepsy, and amyotrophic lateral sclerosis: An epidemiological study. Archives of Neurology 41, 1067-1069.
92. Schiffer RB, Wineman NM (1990). Antidepressant pharmacotherapy of depression associated with multiple sclerosis American Journal of Psychiatry 147, 1493-1497.
93. Schlatter J, Ortuno F, Cervera-Enguix S (2001). Differences in interleukins' patterns between dysthymia and major depression. European Psychiatry 16, 317-319.
94. Schubert DSP, Foliart RH (1993). Increased depression in multiple sclerosis patients: A meta analysis. Psychosomatics 34, 124-130.
95. Seidel A, Arolt V, Hunstiger M, Rink L, Behnisch A, Kirchner H (1996). Major depressive disorder is associated with elevated monocyte counts. Acta Psychiatrica Scandinavica 94, 198-204.
96. Shen Y, Connor TJ, Nolan Y, Kelly JP, Leonard BE (1999). Differential effect of chronic antidepressant treatments on lipopolysaccharide-induced depressive-like behavioural symptoms in the rat. Life Science 17, 1773-1786.
97. Sluzewska A, Rybakowski J, Laciak M, Mackiewicz A, Sobieska M, Wiktorowicz K (1995). Interleukin-6 serum levels in depressed patients before and after treatment with fluoxetine. Annals of the New York Academy of Sciences 762, 474-476.
98. Smith AP, Thomas M, Brockman P, Kent J, Nicholson KG (1993). Effect of influenza B virus infection on human performance. British Medical Journal 306, 760-761.
99. Smith AP, Tyrrell DAJ, Barrow GI (1992). Mood and experimentally induced respiratory virus infections and illness. Psychology and Health 6, 205-212.
100. Smith RS (1991). The macrophage theory of depression. Medical Hypotheses 35, 298-306.
101. Sommer N, Loschmann PA, Northoff GH, Weller M, Steinbrecher A, Steinbach JP, Lichtenfels R, Meyermann R, Riethmuller A, Fontana A, Dichgans J, Martin R (1995). The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis. Nature Medicine 1, 244-248.
102. Song C, Leonard BE (1994). An acute phase protein response in the olfactory bulbectomized rat: Effect of sertraline treatment. Medical Science Research 22, 313-314.
103. Thomas AJ, Ferrier IN, Kalaria RN, Woodward SA, Ballard C, Oakley A, Perry RH, O'Brien JT (2000). Elevation in late-life depression of intercellular adhesion molecule-1 expression in the dorsolateral prefrontal cortex. American Journal of Psychiatry 157, 1682-1684.
104. Valentine AD, Meyers CA, Kling MA, Richelson E, Hauser P (1998). Mood and cognitive side effects on interferon-alpha therapy. Seminars in Oncology 25, 39-47.
105. Van Heeringen K, Zivkov M (1996). Pharmacological treatment of depression in cancer patients. A placebo-controlled study of mianserin. British Journal of Psychiatry 169, 440-443.
106. Watkins LR, Maier SF (1999). Implications of immune-to-brain communication for sickness and pain. Proceedings of the National Academy of Sciences USA 6, 7710-7713.
107. Watkins LR, Nguyen KT, Lee JE, Maier S (1999). Dynamic regulation of proinflammatory cytokines. Advances in Experimental Medicine and Biology 461, 153-178.
108. Weizman R, Laor N, Podliszewski E, Notti I, Djaldetti M, Bessler H (1994). Cytokine production in major depressed patients before and after clomipramine treatment. Biological Psychiatry 35, 42-47.
109. Xia Z, DePierre JW, Nassberger L (1996). Tricyclic antidepressants inhibit IL-6, IL-1β and TNF-α release in human blood monocytes and IL-2 and interferon-γ in T-cells. Immunopharmacology 34, 27-37.
110. Xia Z, Karlsson H, DePierre JW, Nassberger L (1997). Tricyclic antidepressant induce apoptosis in human T lymphocytes. International Journal of Immunopharmacology 19, 645-654.
111. 2, and hyaluronic acid production in human synovial cells and synovial tissue cultures. Arthritis and Rheumatism 42, 2561-2568.
112. Yirmiya R (1996). Endotoxin produces a depressive-like syndrome in rats. Brain Research 711, 163-174.
113. Yirmiya R (1997). Behavioral and psychological effects of immune activation: Implications for 'depression due to a general medical condition'. Current Opinion in Psychiatry 10, 470-476.
114. Yirmiya R (2000). Depression in medical illness: The role of the immune system. Western Journal of Medicine 173, 333-336.
115. Yirmiya R, Pollak Y, Barak O, Avitsur R, Ovadia H, Bette M, Weihe E, Weidenfeld J (2001). Effects of antidepressant drugs on the behavioral and psychological responses to lipopolisaccharide (LPS) in rodents. Neuropsychopharmacology 24, 531-544.
116. Yirmiya R, Pollak Y, Morag M, Reichenberg A, Barak O, Avitsur R, Shavit Y, Ovadia H, Weidenfeld J, Morag A, Newman ME, Pollmacher T (2000). Illness, cytokines and depression. Annals of the New York Academy of Sciences 917, 478-487.
117. Yirmiya R, Weidenfeld J, Pollak Y, Morag M, Morag A, Avitsur R, Barak O, Reichenberg A, Cohen E, Shavit Y, Ovadia H (1999). Cytokines, 'depression due to a general medical condition', and antidepressant drugs. Advances in Experimental Medicine and Biology 461, 283-316.
118. Zaharia MD, Ravindran AV, Griffiths J, Merali Z, Anisman H (2000). Lymphocyte proliferation among major depressive and dysthymic patients with typical or atypical features. Journal of Affective Disorders 58, 1-10.
119. Zhu J, Bengtsson BO, Mix E, Thorell LH, Olsson T, Link H (1994). Effect of monoamine reuptake inhibiting antidepressants on major histocompatibility complex expression on macrophages in normal rats and rats with experimental allergic neuritis (EAN). Immunopharmacology 27, 225-244.
120. Zorrilla EP, Luborsky L, McKay JR, Rosenthal R, Houldin A, Tax A, McCorkle R, Seligman DA, Schmidt K (2001). The relationship of depression and stressors to immunological assays: A meta-analytic study. Brain, Behavior and Immunity 15, 199-226.
121. Zorzenon M, Colle R, Vecchio D, Bertoli M, Giavedoni A, Degrassi A, Lavaroni S, Aguglia E (1996). Major depression, viral reactivation, and immune system. European Psychiatry 11, 332.